China's NMPA Accepts NDA for Gyre Therapeutics' F351 Liver Fibrosis Drug
summarizeSummary
Gyre Therapeutics announced that China's National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for F351 (hydronidone) to treat chronic hepatitis B-induced liver fibrosis. This is a critical regulatory milestone for the company's lead fibrosis candidate, moving it closer to potential commercialization in China. The acceptance follows F351 previously receiving NMPA priority review and demonstrating fibrosis regression in a pivotal Phase 3 trial. This development is highly positive for Gyre, as it significantly de-risks the drug and opens a path to a major market. Investors will now watch for the NMPA's final approval decision and subsequent commercialization plans.
At the time of this announcement, GYRE was trading at $7.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $708.1M. The 52-week trading range was $6.57 to $11.78. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.